Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

Lion0fWallSt Mar. 21 at 9:11 PM

$SLS $CAPR $ATOS $ONDS $CADL @CJ27969 @Fenderstrat68 @MetalFistSlip Cheers! from @p0ppycampbell and @angelplumleyy. Mark this post because those two short sellers are going to take all your money this year.

1 · Reply

Geezer54 Mar. 21 at 8:49 PM

$ATOS This 2nd RS Filing is really a red Flag! This implies their , once respected ,no debt, cash rich, base is healthy... BUT .... it's apparently more likely, this listing is in big trouble... Other scenario, it's more an attractive buy today than after next year's inflated share price.

0 · Reply

JBS_84 Mar. 21 at 6:52 PM

$ATOS I'm not invested here, just checking in. Clearly this company plays way too many games and has completely given up on shareholders. Not a good strategy at all. For anyone. Not for shareholders and not for them. Quay is a world class prick. Washout.

0 · Reply

steven1x Mar. 21 at 6:06 PM

$ATOS that’s a wide spread rs https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526117826/atos-20260320.htm

0 · Reply

steven1x Mar. 21 at 4:27 PM

$ATOS any more updates on breast ? https://www.prnewswire.com/news-releases/atossa-therapeutics-strengthens-clinical-leadership-team-with-the-addition-of-two-experienced-biopharma-executives-302718250.html

1 · Reply

Bunster Mar. 21 at 4:12 PM

$ATOS WEEK IN REVIEW MARCH 20 2026 5.33 PRE RS PPS 36C. RS OPENED US AT 8.40. WEEKS LATER ITS 5.33 A WTF MOMENT AH YESTERDAY WE ARE VOTING FOR ANOTHER RS.RESULTS TO BE ANNOUNCED AT AGM MAY 7. WHEN WILL QUAY DO HIS OFFERING RAISE AND HOW WILL HE DO IT? WE JUST HAD A ATOS WTF MOMENT WHEN MBC WAS PAUSED .LOL. YESTERDAY WE GOT ANOTHER ONE.IF MICHAEL PARKS WERE STILL HERE HE WOULD BE DOING A ZOOM PEPTALK MEETING EVERY WEEK

0 · Reply

Bunster Mar. 21 at 4:02 PM

$ATOS for the 90th time. welcome to quay and atos .VOTING ON ANOTHER RS AFTER JUST HAVING ONE 6 WEEKS AGO.

0 · Reply

NOYES Mar. 21 at 1:49 PM

$ATOS the only time this makes sense is they do the dilution now and use the reverse split already approved from annual shareholders mtng . The new nasdaq rule does not allow 6 month grace period within rs year???

1 · Reply

ofsnp2 Mar. 21 at 9:58 AM

$ATOS What the hell are they trying to do with that vote they just had reverse split and they cant use another one for tbe next year so what is the point of asking now

1 · Reply

ShowMeThaMonay Mar. 21 at 5:09 AM

$ATOS another RS vote already? what a slap in the face to investors. Are they shaking the tree before news? Why have the vote so soon if they can’t even use it. What’s retails motive for voting in favor?

1 · Reply

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Mar 12, 2026, 8:00 AM EDT - 9 days ago

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Feb 11, 2026, 8:30 AM EST - 5 weeks ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Feb 5, 2026, 8:30 AM EST - 6 weeks ago

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Jan 21, 2026, 9:05 AM EST - 2 months ago

Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025

Jan 16, 2026, 4:40 PM EST - 2 months ago

Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy

Jan 6, 2026, 8:15 AM EST - 2 months ago

Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

Dec 17, 2025, 8:15 AM EST - 3 months ago

Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Dec 15, 2025, 8:00 AM EST - 3 months ago

Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Dec 11, 2025, 8:00 AM EST - 3 months ago

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Dec 9, 2025, 8:00 AM EST - 3 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

Dec 4, 2025, 8:00 AM EST - 3 months ago

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 3 months ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 4 months ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:15 AM EST - 4 months ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 4 months ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 5 months ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 5 months ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 6 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 6 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 6 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 7 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 7 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 7 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 8 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 10 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 10 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 11 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 11 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 11 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 11 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 11 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 1 year ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 1 year ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 1 year ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 1 year ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 1 year ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Lion0fWallSt Mar. 21 at 9:11 PM

1 · Reply

Geezer54 Mar. 21 at 8:49 PM

0 · Reply

JBS_84 Mar. 21 at 6:52 PM

0 · Reply

steven1x Mar. 21 at 6:06 PM

$ATOS that’s a wide spread rs https://www.sec.gov/ix?doc=/Archives/edgar/data/0001488039/000119312526117826/atos-20260320.htm

0 · Reply

steven1x Mar. 21 at 4:27 PM

1 · Reply

Bunster Mar. 21 at 4:12 PM

0 · Reply

Bunster Mar. 21 at 4:02 PM

$ATOS for the 90th time. welcome to quay and atos .VOTING ON ANOTHER RS AFTER JUST HAVING ONE 6 WEEKS AGO.

0 · Reply

NOYES Mar. 21 at 1:49 PM

1 · Reply

ofsnp2 Mar. 21 at 9:58 AM

$ATOS What the hell are they trying to do with that vote they just had reverse split and they cant use another one for tbe next year so what is the point of asking now

1 · Reply

ShowMeThaMonay Mar. 21 at 5:09 AM

1 · Reply

TheSilentVoid Mar. 21 at 2:49 AM

$ATOS Vote must have been too close last time. 😆. The ignorance of retail shareholders will prevail once again.

0 · Reply

TheChangedBear Mar. 21 at 2:34 AM

$ATOS MB is just fine Dumpster. Typical idiots, but they dont use CAPSLOCK like a moron.

0 · Reply

Bunster Mar. 21 at 1:52 AM

$ATOS mb is dead we are voting on another rs and only 3 people here are discussing it . me dawg and kitty

1 · Reply

Kittyc803 Mar. 21 at 12:43 AM

$ATOS So just read the filing . Even if clowns vote yes like last time to have an RS in their pocket . Can’t be used till May 7th 2027 . Who cares ? He doesn’t show huge progress in the next 6 months im out anyway ,

4 · Reply

Kittyc803 Mar. 21 at 12:27 AM

$ATOS Haven’t seen the filing yet but if true . Why he wants a split in his pocket beying me 🤷‍♂️ 1) under 2025 new listing rules. You can’t use it for a year after the first one . 2) we fall under a $1 gor 30 days automatic delisting . Having a split in hand won’t help him . Remember the new rules we got the shaft after hitting 10 days 🤦‍♂️

3 · Reply

Kittyc803 Mar. 21 at 12:15 AM

$ATOS Hey what did i miss . Wasn’t on today .

3 · Reply

Bunster Mar. 21 at 12:07 AM

$ATOS why we are voting for another rs is clear to prime. They want us to vote when the pps is 5 dollars not if the pps is 60c after a possible huge dilutive offering . plus the other reasons i discussed with dawg. REMEMBER GIRLS A FRIDAY AH FILING AINT GOOD

2 · Reply

Uberdawg Mar. 21 at 12:06 AM

$ATOS They did say that the purpose of the rs would be to maintain NASD compliance. Don’t get it. Maybe they will explain

1 · Reply

hvlgroup Mar. 20 at 11:54 PM

$ATOS Sorry. I did find it. That would be the rape of the current investors who stayed loyal through the recent RS. Can that be legal? Many of us would be left with less than 500 shares and need a SP of of over $300 + to break even. If these assholes do this, its definitely time for a class action suit. We have nothing to lose.

0 · Reply

hvlgroup Mar. 20 at 11:45 PM

$ATOS I'd like to weigh in but i looked everywhere and found nothing about a new request for an RS. The Atossa Theraputics website shows nothing about it. Please send a verifiable news link, not AI. Thanks.

1 · Reply

Uberdawg Mar. 20 at 10:37 PM

$ATOS Ah, yes. The dreaded “after hours “ Announcement. And a request for an unneeded authority for a rs. Just in anticipation of low probability future need?? A scare tactic to promote selling?? Maybe the “B Man will weigh in with Primes thoughts. Kitty, 2tm, hvl, any theories. This baffles me. I see no sense in it. However, I have only thought about it for a few minutes. Time will reveal all. I hope Everyone be well

3 · Reply

DaddywarbucksX3 Mar. 20 at 7:26 PM

$ATOS FTW

0 · Reply

Market Cap	44.01M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	159,400
Avg Vol	153,963
Day's Range	N/A - N/A
Shares Out	8.61M
Stochastic %K	54%
Beta	1.42
Analysts	Strong Sell
Price Target	$15.00